In this video, Fool.com analysts David Williamson and Max Macaluso discuss United Therapeutics and Discovery Laboratories' 15% intraday plunges. One received an FDA rejection and the other had a familiar problem rear its ugly head. Watch and find out what this means for these stocks, their competitors, and investors.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.